Associated Papers
Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally.
Kawashima S et al.
Biochemical and Biophysical Research Communications, 2023
"Mutation blacklist" and "mutation whitelist" of SARS-CoV-2.
Sun Y et al.
Journal of Biosafety and Biosecurity, 2022
35845149 (PubMed )
Supplement: mmc4.pdf
The first three waves of the Covid-19 pandemic hint at a limited genetic repertoire for SARS-CoV-2.
Wassenaar TM et al.
Fems Microbiology Reviews, 2022
A New Way to Trace SARS-CoV-2 Variants Through Weighted Network Analysis of Frequency Trajectories of Mutations.
Huang Q et al.
Frontiers in Microbiology, 2022
35369526 (PubMed )
Supplement: Table_2.XLSX › TS2
Nucleocapsid mutations R203K/G204R increase the infectivity, fitness, and virulence of SARS-CoV-2.
Wu H et al.
Cell Host & Microbe, 2021
34822776 (PubMed )
Supplement: mmc2.xlsx › ST1A
SARS-CoV-2 genetic variations associated with COVID-19 pathogenicity.
Aiewsakun P et al.
Microbial Genomics, 2021
Mutation Signatures and In Silico Docking of Novel SARS-CoV-2 Variants of Concern.
Shahhosseini N et al.
Microorganisms, 2021
A Potential SARS-CoV-2 Variant of Interest (VOI) Harboring Mutation E484K in the Spike Protein Was Identified within Lineage B.1.1.33 Circulating in Brazil.
Resende PC et al.
Viruses, 2021
33919314 (PubMed )
Supplement: viruses-13-00724-s001.zip › Resende_20210317_SupMaterial › SupplementaryTableS2.docx
Select a paper to view details